期刊
HEMATOLOGICAL ONCOLOGY
卷 36, 期 5, 页码 773-778出版社
WILEY
DOI: 10.1002/hon.2550
关键词
elderly patients; maintenance rituximab; mantle cell lymphoma; minimal residual disease; PET-CT
资金
- Ministry of Health of the Czech Republic [AZV 17-28980A]
- Charles University Center of Excellence [UNCE/MED/016]
- Ministry of Education, Youth, and Sports [PROGRES Q26/LF1, PROGRES Q28/LF1]
- Grant Agency of Charles University [GAUK 20214]
- Ministry of Education, Youth, and Sports NPU I [LO1604]
- EU-Prague project [CZ.2.16/3.1.00/24505]
- project for conceptual development of research organization [00064203]
- [GBP302/12/G101]
Rituximab maintenance (RM) prolongs survival of elderly patients with mantle cell lymphoma (MCL). Persistent minimal residual disease (MRD) after induction repeatedly correlated with shorter progression-free survival (PFS). However, none of the published studies analyzed patients treated with RM. The main purpose was to analyze prognostic significance of MRD in the elderly patients with newly diagnosed MCL treated according to the recently published observational trial protocol (alternation of R-CHOP and R-cytarabine, 3 + 3 cycles, GovTrial number NCT03054883) at the centers that implemented RM. Minimal residual disease was evaluated by a EuroMRD standardized real-time PCR approach after 3 and 6 cycles of the induction therapy. Prognostic significance of MRD was analyzed in a subcohort of patients treated at the centers that implemented RM as a standard approach. Bone marrow proved to be a significantly more sensitive source for MRD detection than peripheral blood. In either compartment MRD (positive versus negative) after 3 or 6 cycles of the induction therapy did not correlate with PFS. The observed loss of prognostic significance of MRD after the R-CHOP-based induction appears to be a consequence of RM immune control over the residual lymphoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据